CD­MO se­cures a $98M+ NIH con­tract for pro­duc­tion of pe­di­atric HIV-pre­ven­tion prod­ucts

Ad­vanced Bio­Science Lab­o­ra­to­ries, a CD­MO spe­cial­iz­ing in bio­ther­a­pies, vi­ral vec­tor-based vac­cines and on­colyt­ics, has re­ceived a de­vel­op­ment and man­u­fac­tur­ing con­tract from the US gov­ern­ment.

ABL has been award­ed a sev­en-year con­tract with a po­ten­tial val­ue of $98.9 mil­lion to pro­vide re­sources to Pe­di­atrics and HIV Pre­ven­tion Sci­ence by the Na­tion­al In­sti­tutes of Health’s Di­vi­sion of AIDS. Specif­i­cal­ly, ABL will pro­vide the Di­vi­sion of AIDS with pre­clin­i­cal work, an­i­mal mod­els and an­a­lyt­i­cal ser­vices man­u­fac­tur­ing to ad­vance non-vac­cine bio­med­ical HIV prod­ucts such as in­trav­agi­nal rings and long-act­ing in­jecta­bles that aim to pre­vent STIs, HIV or preg­nan­cy.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters